Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease

BACKGROUND: Dysregulation of innate and adaptive immunity heralds both the development and progression of Parkinson's disease (PD). Deficits in innate immunity in PD are defined by impairments in monocyte activation, function, and pro‐inflammatory secretory factors. Each influences disease path...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelmoaty, Mai M., Machhi, Jatin, Yeapuri, Pravin, Shahjin, Farah, Kumar, Vikas, Olson, Katherine E., Mosley, R. Lee, Gendelman, Howard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270000/
https://www.ncbi.nlm.nih.gov/pubmed/35802825
http://dx.doi.org/10.1002/ctm2.958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270000/
https://www.ncbi.nlm.nih.gov/pubmed/35802825
http://dx.doi.org/10.1002/ctm2.958

Ejemplares similares